Jan 13, 2023 15:06 JST

Source: Eisai

Eisai Launches Renewed Sustainability Page

TOKYO, Jan 13, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced that it has renewed the Sustainability page of its corporate website and it is now accessible to the public.

 


Sustainability Top Page
www.eisai.com/sustainability/index.html

The Eisai's Corporate Concept is "to give first thought to patients and the people in the daily living domain, and to increase the benefits that health care provides to them". Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. For realizing our corporate concept, it is necessary to implement corporate measures based on a long-term perspective under a well-cultivated governance structure. Therefore, it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues.

In order to provide information about our sustainability approach and activities in an easy-to-understand manner, we have enhanced the content, and renewed the key visuals, design and page structure. We have also featured our approach, targets and initiatives for improving access to medicines, which Eisai is focusing on, as well as the areas of environment, society and governance.

Through further efforts in our proactive disclosure of information for sustainability, we will aim to develop and maintain favorable relations with all of our stakeholders.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
April 18 2024 09:53 JST
 
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
April 17 2024 15:17 JST
 
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
April 03 2024 15:24 JST
 
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
April 01 2024 08:39 JST
 
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
March 29 2024 14:51 JST
 
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
March 29 2024 14:19 JST
 
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
March 29 2024 13:32 JST
 
Lifenet and Eisai Co-Develop Dementia Insurance "be"
March 21 2024 16:36 JST
 
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
March 21 2024 15:10 JST
 
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
March 06 2024 16:47 JST
 
More Press release >>

Latest Press Release


More Latest Release >>